Back to Search
JOSE CORTES, MD
MD
General Practice Physician
NPI: 1790443729Individual
Specialties, Licenses & Credentials
General Practice PhysicianPrimary
General Practice
Code: 208D00000X
22905(PR)
Research & Publications (20)
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
PMID 19508387·J Cell Mol Med·2010
7-preclinical
Azacitidine for the treatment of myelodysplastic syndrome.
PMID 19589026·Expert Rev Anticancer Ther·2009
6-review
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
PMID 19487385·J Clin Oncol·2009
3-trial
Island parity. Puerto Rico needs full payments from federal programs.
PMID 19606669·Mod Healthc·2009
8-other
Trends in healthcare utilization for diarrhea and rotavirus disease in privately insured US children <5 years of age, 2001-2006.
PMID 19590460·Pediatr Infect Dis J·2009
8-other
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
PMID 19652056·J Clin Oncol·2009
3-trial
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
PMID 19536906·Cancer·2009
3-trial
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
PMID 19536894·Cancer·2009
3-trial
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
PMID 19531657·Blood·2009
8-other
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
PMID 19517473·Cancer·2009
3-trial
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
PMID 19517462·Cancer·2009
8-other
Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma.
PMID 19665777·J Allergy Clin Immunol·2009
7-preclinical
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
PMID 19506164·J Clin Oncol·2009
4-observational
Optimizing first-line therapy for patients with chronic myeloid leukemia.
PMID 19621543·Semin Hematol·2009
8-other
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
PMID 19487383·J Clin Oncol·2009
4-observational
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
PMID 19484334·Int J Hematol·2009
3-trial
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.
PMID 19480932·Cancer Genet Cytogenet·2009
5-case
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
PMID 19679008·Curr Oncol Rep·2009
6-review
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
PMID 19652654·Nat Rev Clin Oncol·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 80 CALLE NUEVO LONDRES
UTUADO, PR 00641 - Phone
- (787) 894-8492
Quick Facts
- NPI
- 1790443729
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile